Patents for A61P 35 - Antineoplastic agents (221,099)
02/2008
02/14/2008US20080039440 such as 6-(6-Amino-pyrimidin-4-yloxy)-3,4-dihydro-2H-quinoline-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide, used for the treatment of leukemia
02/14/2008US20080039436 Porphyrin Derivatives And Their Use In Photon Activation Therapy
02/14/2008US20080039429 Sulfonylethyl phosphorodiamidates
02/14/2008US20080039427 Method and compositions for treating hematological malignancies
02/14/2008US20080039426 2-(4-fluoro-2-methylphenylamino)-1,6-dimethyl-7-[3-(4-methyl-4-oxo-4 lambda 5[1,4]azaphosphinan-1-yl)-propenyl]-1,8-dihydro-imidazo[4,5-h]isoquinolin-9-one; anticancer agents, antiinflammatory agents, antiviral agents, anti-thromboembolic agents, as well as for treating autoimmune disease
02/14/2008US20080039421 Molecular Transporters Based On Alditol Or Inositol And Processes For The Preparation Thereof
02/14/2008US20080039419 Integrin-linked kinase and its uses
02/14/2008US20080039417 Protein Tyrosine Phosphate Mutations in Cancers
02/14/2008US20080039416 Methods for Treating Disease by Modulating an Osmotic Stress Pathway
02/14/2008US20080039413 Novel compositions and methods in cancer
02/14/2008US20080039409 Method of Suppressing Cancer
02/14/2008US20080039408 Use of Oxypurinol as an Inhibitor of Anti-Neoplastic Agent-Induced Cardiotoxicity
02/14/2008US20080039403 Exposing the cancer cell to a peptide has antiestrotrophic activity; inhibit estrogen receptor dependent cell proliferation; breast cancer
02/14/2008US20080039394 Dendroaspis natriuretic peptide
02/14/2008US20080039392 CRAC channel and modulator screening methods
02/14/2008US20080039384 Antiangiogenic Peptides
02/14/2008US20080039381 Lactalbumin for Inhibiting Angiogenesis
02/14/2008US20080039372 Human chorionic gonadotropin antagonists and methods to prevent ovarian hyperstimulation
02/14/2008US20080039363 administering angiotensinogen; pluripotent stem cell transplantation; for supporting bone marrow transplantation, and promoting megakaryocyte production and mobilization and platelet production; improved leukocyte production
02/14/2008US20080038819 Micro Rna Inhibiting the Expression of Wt1 Gene and Utilization of the Same
02/14/2008US20080038387 Therapy of estrogen-associated disorders
02/14/2008US20080038385 Therapeutic uses of an anti-cancer composition derived from rice bran
02/14/2008US20080038376 Anti-cancer composition and method for using the same
02/14/2008US20080038369 Methods And Compositions For The Treatment Of Prolactin-Receptor Related Disorders
02/14/2008US20080038361 Water-Soluble Nanoparticles Stabilized with Multi-Functional Group Ligands and Method of Preparation Thereof
02/14/2008US20080038312 Insertable or implantable medical devices suitable for gene therapy regimens
02/14/2008US20080038309 Use of polypeptides obtained through systematic mutations of single amino acids of human and non-human Box-A of HMGB1 to prevent and/or antagonize pathologies induced by HMGB1
02/14/2008US20080038289 Antitumor Agent
02/14/2008US20080038285 Method for Identifying and Quantifying of Tumour-Associated
02/14/2008US20080038283 Methods of Evaluating Efficacy of an Immune Response by Assesing Alpha-1 Integrin Expression
02/14/2008US20080038281 Model membrane systems
02/14/2008US20080038271 Extending survival of cancer patients with elevated levels of EGF or TGF-alpha
02/14/2008US20080038267 Treatment Of Cancer
02/14/2008US20080038263 Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas
02/14/2008US20080038261 Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
02/14/2008US20080038260 specifically bind to monocyte-derived dendritic cells (MDDC); immunostimulants; downmodulating transplant rejection; cancer
02/14/2008US20080038256 having the equal or greater binding activity than that of the parent antibody with reduced immunogenicity in human; HGF/SF (hepatocyte growth factor/scatter factor); cancer
02/14/2008US20080038248 Proteins Ligands For Nkg2d And Ul16 Receptors And Uses Thereof
02/14/2008US20080038247 Diagnostics and Therapeutics for Diseases Associated With G-Protein-Coupled Receptor Gpr39 (Gpr39)
02/14/2008US20080038244 Materials and Methods Relating to Cell Cycle Control
02/14/2008US20080038234 Bone Marrow-Related Cells Associated With Tissue Maintenance And/Or Repair
02/14/2008US20080038231 Processing procedure for peripheral blood stem cells
02/14/2008US20080038224 Modified interferon-beta (IFN-beta) polypeptides
02/14/2008US20080038223 WSX-1/P28 as a target for anti-inflammatory responses
02/14/2008US20080038203 Compositions and Methods for Topical Diagnostic and Therapeutic Transport
02/14/2008US20080038189 RNA interference mediated inhibition of aurorakinase B and its combinations as anticancer therapy
02/14/2008DE102006037478A1 2-(Heterocyclylbenzyl)-pyridazinonderivate 2- (Heterocyclylbenzyl) -pyridazinone derivatives
02/14/2008CA2836006A1 Use of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment of mantle cell lymphomas
02/14/2008CA2661131A1 New heterocyclic compounds containing nitrogen atoms or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same for treatment of cancer
02/14/2008CA2660658A1 Osmium compounds
02/14/2008CA2660636A1 Nucleosides, drugs containing these and use thereof
02/14/2008CA2660356A1 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
02/14/2008CA2660324A1 Plasmids with immunological action
02/14/2008CA2660232A1 Structure and use of 5' phosphate oligonucleotides
02/14/2008CA2660102A1 Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
02/14/2008CA2659894A1 Heteroaryl compounds useful as inhibitors of e1 activating enzymes
02/14/2008CA2659820A1 Ephb3-specific antibody and uses thereof
02/14/2008CA2659774A1 Use of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment of mantle cell lymphomas
02/14/2008CA2659631A1 Antibodies to erbb2
02/14/2008CA2659604A1 Pyrimidine derivative as pi3k inhibitor and use thereof
02/14/2008CA2659598A1 Amino phosphate derivative and s1p receptor modulator having same as an active ingredient
02/14/2008CA2659429A1 4-oxo-4,5-dihydropyrrolo[1,2-a]quinoxaline derivatives as inhibitors of poly(adp-ribose)polymerase(parp)
02/14/2008CA2658285A1 Thieno[3,2-c]pyridine-7-carboxylic acid derivatives for use in treating solid tumors
02/14/2008CA2657763A1 Anti-il-6 monoclonal antibodies and uses thereof
02/13/2008EP1887084A1 Plasmids with immunological action
02/13/2008EP1887082A2 TADG-15: An extracellular serine protease overexpressed in carcinomas
02/13/2008EP1887016A1 Fragments of human chorionic gonadotropin (hcg) as immunoregulator
02/13/2008EP1886993A1 Benzo[f]isoindole derivatives with affinity to the ep4 receptor
02/13/2008EP1886689A1 Oxidative stress inhibitor
02/13/2008EP1886688A1 Method for producing nucleic acid-containing complex preparation
02/13/2008EP1886681A2 New nuclear transcription factors regulators
02/13/2008EP1886677A1 Use of an inducing agent for the treatment of blood, viral and cellular disorders
02/13/2008EP1885855A2 Cytokine receptor modulators and uses thereof
02/13/2008EP1885725A1 Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
02/13/2008EP1885723A2 Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors
02/13/2008EP1885719A1 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
02/13/2008EP1885717A1 Shp-2 inhibitors, pharmaceutical compositions comprising them and their use for treating phosphatase-mediated diseases
02/13/2008EP1885710A1 Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
02/13/2008EP1885702A2 Quinazolinones
02/13/2008EP1885389A1 Use of adnf polypeptides for treating peripheral neurotoxicity
02/13/2008EP1885380A1 Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment of urogenital cancer and its metastasis
02/13/2008EP1885372A2 Uses of prostacyclin analogs
02/13/2008EP1885364A1 Halogenated quindoline dimers for the treatment of cancer
02/13/2008EP1885355A1 Anticancer combination therapy using sunitinib malate
02/13/2008EP1885352A2 Combinations comprising jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
02/13/2008EP1885349A2 Sulphamides for treatment of cancer
02/13/2008EP1885337A2 Medicament, particularly an anti-cancer medicament, for treatment using immunotherapy, particularly autologous
02/13/2008EP1750735B1 Use of an extract of aloysia/verbrena/lippia triphylla/citridora for the preparation of a medicament for the treatment of chronic and/or inflammatory diseases
02/13/2008EP1651227B1 Pharmaceutical compositions comprising azd 2171 and zd 6126 and uses thereof
02/13/2008EP1553940B1 Parenteral formulations containing a rapamycin hydroxyester
02/13/2008EP1517699B1 Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation
02/13/2008EP1517679B1 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
02/13/2008EP1470148A4 Double-stranded oligonucleotides
02/13/2008EP1454137B1 Use of a labeled ligand having human cd4 specificity for producing a diagnostic used in the analysis of migration and/or distribution patterns of cell populations
02/13/2008EP1450814A4 Methods of inhibiting metastases
02/13/2008EP1437944B1 Process for the fractionation of oilseed press cakes and meals
02/13/2008EP1432677B1 Novel urea oligomers, the preparation method thereof and pharmaceutical compositions containing same
02/13/2008EP1427739A4 Targeted bisplatinum polyamines as pro-drugs: selective release of platinum
02/13/2008EP1404650B1 Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments
02/13/2008EP1373234B1 Urokinase inhibitors